Manager, R&D Finance
Alnylam Pharmaceuticals
Summary
The Manager of R&D Finance is a key member of Alnylam's Financial Planning and Analysis team, partnering with business leaders across the organization. The primary focus of this role is providing strategic finance business partner support to the Development organization & to the broader R&D finance team.
Job description
Overview
The Manager of R&D Finance is a key member of Alnylam's Financial Planning and Analysis team, partnering with business leaders across the organization. The primary focus of this role is providing strategic finance business partner support to the Development organization & to the broader R&D finance team.
This is a hybrid position and will be primarily based in Cambridge, MA.
Responsibilities
- Serve as finance business partner to the assigned Development functions, providing oversight of actual spend vs. budget, reforecasting, long-range planning, and strategic decision support.
- Partner with Clinical Operations therapeutic area leaders to deliver accurate clinical trial expense accruals and forecasts, working closely with accounting, sourcing, business operations, and other key stakeholders.
- Collaborate with functional, program, and finance partners to deliver timely, accurate, and actionable financial analysis that informs R&D governance discussions and decision-making.
- Support broader R&D finance team deliverables, including consolidation and reporting for R&D functions and programs.
- Prepare recurring and ad hoc presentations for internal and external stakeholders, including executive-level audiences.
- Drive continuous improvement in finance processes and reporting, partnering with stakeholders across Finance to implement changes that improve efficiency and communication.
Qualifications
- Bachelor's degree, preferably in Finance or Accounting.
- 5+ years of relevant financial experience (e.g., Corporate Finance, FP&A, Accounting), or an equivalent combination of education and experience.
- Experience in the biotech/pharma industry, with R&D experience strongly preferred.
- Strong understanding of accounting and finance principles, with strong financial analysis and data interpretation skills.
- Strong written and verbal communication skills, with a collaborative approach to sharing insights and delivering on project timelines.
- Ability to manage multiple assignments and competing priorities under tight deadlines.
- Advanced proficiency in Microsoft Excel and PowerPoint.
- Experience with SAP and Adaptive Planning is a plus.
Requirements
- Bachelor's degree, preferably in Finance or Accounting
- 5+ years of relevant financial experience (e.g., Corporate Finance, FP&A, Accounting), or an equivalent combination of education and experience
- Experience in the biotech/pharma industry, with R&D experience strongly preferred
- Strong understanding of accounting and finance principles
- Strong financial analysis and data interpretation skills
- Strong written and verbal communication skills
- Collaborative approach to sharing insights and delivering on project timelines
- Ability to manage multiple assignments and competing priorities under tight deadlines
- Advanced proficiency in Microsoft Excel and PowerPoint
- Experience with SAP and Adaptive Planning is a plus
Benefits
- Medical, Dental & Vision
- Life & Disability Insurance
- Lifestyle Reimbursement Program
- Flexible Spending Accounts
- Health Savings Accounts
- 401(k) Matching
- Paid Time Off
- Wellness Days
- Holidays
- Company-wide Recharge Breaks
- Family Resources
- Leave
Company overview
Alnylam Pharmaceuticals is a pioneering American biopharmaceutical company and the global leader in RNA interference (RNAi) therapeutics. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam has revolutionized the field of genetic medicine by developing innovative treatments that 'silence' disease-causing genes. The company achieved a historic milestone in 2018 with the approval of Onpattro (patisiran), the world's first RNAi therapeutic, which treats hereditary transthyretin-mediated amyloidosis. Since then, Alnylam has successfully commercialized five additional RNAi medicines targeting rare genetic disorders including acute hepatic porphyria, primary hyperoxaluria type 1, and transthyretin amyloidosis. With over 2,100 employees worldwide, Alnylam maintains a robust pipeline of investigational therapies across genetic medicines, cardiometabolic diseases, and hepatic infectious diseases. The company's groundbreaking work has established RNAi as a clinically validated therapeutic platform, earning recognition as one of the most innovative biopharmaceutical companies and consistently ranking as a top employer in the life sciences industry.